Emboline Announces First Patient Treated in IDE Study of Emboliner® Full-Body Embolic Protection Catheter to Minimize Stroke Risk From TAVR

2023-05-09

临床研究

SANTA CRUZ, Calif., May 9, 2023 /PRNewswire/ -- Emboline, Inc., a privately held medical technology company focused on reducing stroke during structural heart procedures such as transcatheter aortic valve replacement (TAVR), today announced the first patient has been treated in the Protect the Head to Head investigational device exemption (IDE) clinical trial (NCT05684146) at New York-Presbyterian Hospital/Columbia University Medical Center in New York, NY.

Emboline received IDE approval for the study from the US Food and Drug Administration (FDA) in December 2022. The Emboliner is the first device to provide full brain and body protection from ischemic events such as stroke caused by embolic debris released into the bloodstream during transcatheter heart procedures.

First Patient Treated in IDE Study of Emboliner® Full-Body Embolic Protection Catheter to Minimize Stroke Risk From TAVR

Tweet this

The Protect the Head to Head IDE trial is a prospective, randomized, open label, multicenter, 2-arm study to demonstrate safety and effectiveness of the Emboliner Embolic Protection Catheter compared to the control device (Sentinel CPS) for patients undergoing TAVR. 500 patients will be enrolled in the study at up to 20 centers worldwide. Study endpoints include 30-day major adverse cardiac and cerebrovascular events (MACCE), 30-day VARC-2 stroke and acute embolic debris captured.

"This is a major step towards US approval and commercialization of the Emboliner," said Scott Russell, President and CEO of Emboline. "Stroke remains both a significant risk and fear for patients undergoing TAVR. In our previous SafePass clinical studies, the Emboliner captured and removed more than five times the clinically relevant embolic particles compared to published data for a commercially available device offering partial brain protection. This is consistent with the predicted difference based on arterial blood flow and suggests a significant advantage for patients treated with the Emboliner. We are grateful for the support of our investors and principal investigators and look forward to working with the participating hospitals and investigators on this important trial."

Tamim Nazif, MD, Director of Clinical Research in Cardiology at Columbia University Irving Medical Center and Co-Principal Investigator for the Protect the Head to Head study treated the first study patient. "The Emboliner represents a major advance in embolic protection for cardiovascular procedures by providing full brain and body protection, leaving no major artery to the brain, kidneys or lower body unprotected. The device has shown promising results in the smaller SafePass feasibility studies and we look forward to the results of this pivotal randomized trial as we seek to bring this exciting new technology to our patients."

"The mounting body of evidence on embolic protection devices suggests that embolic protection is no longer considered controversial or optional, it's just the right thing to do to protect your patients from the very real risk of stroke," said Alexandra J. Lansky, MD, FACC, FSCAI, Professor of Medicine (Cardiology), Director of the Clinical Research Program at Yale University School of Medicine, and Principal Investigator for the trial. "The Emboliner represents a new generation in embolic protection devices by fulfilling an unmet need in providing full brain and body protection from stroke and other ischemic events caused by debris released during TAVR. We look forward to the study results."

About Emboline

Emboline, Inc., is a privately held medical technology company that has developed the Emboliner® Embolic Protection Catheter, the first embolic protection device to provide full brain and body embolic protection by capturing and removing all debris from transcatheter procedures that would otherwise travel to the brain, kidneys and other critical organs, and reducing the incidence of stroke, cerebral ischemia, cognitive decline and other adverse outcomes associated with procedure-related emboli. Emboline's technologies are derived from intellectual property invented by Amir Belson, MD, founder of NeoGuide Systems, Vascular Pathways, ZipLine Medical, Qool Therapeutics, Radiaction and others. More information is available at www.emboline.com.

The Emboliner® is not commercially available and is intended for investigational use only. Emboliner is a registered trademark of Emboline, Inc.

Media Contact for Emboline: [email protected]

SOURCE Emboline, Inc.